Karolinska Development appoints Johan Dighed as General Counsel
STOCKHOLM – Mars 9, 2020 - Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that it has appointed Johan Dighed as General Counsel. Mr Dighed will join the Company from May 1, 2020. Mr Dighed will replace Mr Richenberg who will retire after more than 10 years with Karolinska Development.
Johan Dighed is an experienced financial legal counsel and banker. He will join Karolinska Development AB from Skandinaviska Enskilda Banken AB, one of the largest banks in the Nordics. He has worked with SEB since 2004 and have had several positions within the Legal department of the Large Corporates and Financial Institutions division of SEB, mainly focusing on Swedish and European structured finance in connection with loans and acquisition financing in different business areas i.a. the business area Venture Capital. His current position with SEB is Head of Corporate Law and Governance for the Large Corporates and Financial Institutions division. During 2014-2017 he was the Head of Legal of SEB AG, a German bank, fully owned subsidiary of SEB. Prior to joining SEB he has worked with the international law firm Baker & McKenzie and in the Swedish Judiciary.
Viktor Drvota, CEO, comments: "I am very pleased that Johan will join Karolinska Development. His knowledge and experience will be very important in our work to develop the company and to generate exits from our portfolio. I would also like to thank Ulf for his work over the years and to wish him a long, happy and well-deserved retirement.”
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: 2, e-mail:
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit
Attachment
